| # | Title | Journal | Year | Citations |
|---|
| 1 | Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics | Pharmacogenomics and Personalized Medicine | 2014 | 106 |
| 2 | H3Africa: current perspectives | Pharmacogenomics and Personalized Medicine | 2018 | 101 |
| 3 | Association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: review of psychopathology and pharmacotherapy | Pharmacogenomics and Personalized Medicine | 2012 | 95 |
| 4 | Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties | Pharmacogenomics and Personalized Medicine | 2014 | 93 |
| 5 | Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways | Pharmacogenomics and Personalized Medicine | 2014 | 83 |
| 6 | Emerging biomarkers in the diagnosis of prostate cancer | Pharmacogenomics and Personalized Medicine | 2018 | 71 |
| 7 | Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics | Pharmacogenomics and Personalized Medicine | 2016 | 69 |
| 8 | Implementation and utilization of genetic testing in personalized medicine | Pharmacogenomics and Personalized Medicine | 2014 | 63 |
| 9 | ABCG2 polymorphisms in gout: insights into disease susceptibility and treatment approaches | Pharmacogenomics and Personalized Medicine | 2017 | 63 |
| 10 | Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway | Pharmacogenomics and Personalized Medicine | 2014 | 60 |
| 11 | Glioblastoma extracellular vesicles: reservoirs of potential biomarkers | Pharmacogenomics and Personalized Medicine | 2014 | 59 |
| 12 | UGT1A1 polymorphisms in cancer: impact on irinotecan treatment | Pharmacogenomics and Personalized Medicine | 2017 | 53 |
| 13 | The current and future state of companion diagnostics | Pharmacogenomics and Personalized Medicine | 2015 | 51 |
| 14 | Role of pharmacogenomics in the treatment of tuberculosis: a review | Pharmacogenomics and Personalized Medicine | 2012 | 46 |
| 15 | Pharmacogenomics of statins: understanding susceptibility to adverse effects | Pharmacogenomics and Personalized Medicine | 2016 | 46 |
| 16 | <p>Inconsistency in race and ethnic classification in pharmacogenetics studies and its potential clinical implications</p> | Pharmacogenomics and Personalized Medicine | 2019 | 44 |
| 17 | <p>Challenges and Future Prospects of Precision Medicine in Psychiatry</p> | Pharmacogenomics and Personalized Medicine | 2020 | 42 |
| 18 | Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy | Pharmacogenomics and Personalized Medicine | 2011 | 40 |
| 19 | DNA methylation at the mu-1 opioid receptor gene (OPRM1) promoter predicts preoperative, acute, and chronic postsurgical pain after spine fusion | Pharmacogenomics and Personalized Medicine | 2017 | 40 |
| 20 | ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics | Pharmacogenomics and Personalized Medicine | 2012 | 39 |
| 21 | <p>Personalized medicine in breast cancer: pharmacogenomics approaches</p> | Pharmacogenomics and Personalized Medicine | 2019 | 39 |
| 22 | Delivering pharmacogenetic testing in a primary care setting | Pharmacogenomics and Personalized Medicine | 2013 | 37 |
| 23 | Angiotensin System Polymorphisms’ in SARS-CoV-2 Positive Patients: Assessment Between Symptomatic and Asymptomatic Patients: A Pilot Study | Pharmacogenomics and Personalized Medicine | 2021 | 37 |
| 24 | CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment | Pharmacogenomics and Personalized Medicine | 2018 | 36 |
| 25 | The effect of ABCB1 polymorphisms on the outcome of breast cancer treatment | Pharmacogenomics and Personalized Medicine | 2016 | 35 |
| 26 | Update on the clinical utility of an RNA interference-based treatment: focus on Patisiran | Pharmacogenomics and Personalized Medicine | 2017 | 35 |
| 27 | The impact of <em>ABCB1</em> (rs1045642 and rs4148738) and <em>CES1</em> (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty | Pharmacogenomics and Personalized Medicine | 2018 | 34 |
| 28 | Finally sofosbuvir: an oral anti-HCV drug with wide performance capability | Pharmacogenomics and Personalized Medicine | 2014 | 31 |
| 29 | Olaparib in the management of ovarian cancer | Pharmacogenomics and Personalized Medicine | 2015 | 31 |
| 30 | The <em>HLA-A*31:01</em> allele: influence on carbamazepine treatment | Pharmacogenomics and Personalized Medicine | 2017 | 31 |
| 31 | Precision pharmacotherapy: psychiatry’s future direction in preventing, diagnosing, and treating mental disorders | Pharmacogenomics and Personalized Medicine | 2018 | 31 |
| 32 | ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer | Pharmacogenomics and Personalized Medicine | 2011 | 30 |
| 33 | Non-small-cell lung cancer: molecular targeted therapy and personalized medicine – drug resistance, mechanisms, and strategies | Pharmacogenomics and Personalized Medicine | 2013 | 30 |
| 34 | Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer | Pharmacogenomics and Personalized Medicine | 2014 | 30 |
| 35 | CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment | Pharmacogenomics and Personalized Medicine | 2018 | 30 |
| 36 | Simeprevir for the treatment of hepatitis C virus infection | Pharmacogenomics and Personalized Medicine | 2014 | 29 |
| 37 | Potential utility of precision medicine for older adults with polypharmacy: a case series study | Pharmacogenomics and Personalized Medicine | 2016 | 29 |
| 38 | Ofatumumab: a novel monoclonal anti-CD20 antibody | Pharmacogenomics and Personalized Medicine | 2010 | 28 |
| 39 | Role of 5-HT2C receptor gene variants in antipsychotic-induced weight gain | Pharmacogenomics and Personalized Medicine | 2011 | 28 |
| 40 | Diet and lifestyle factors associated with miRNA expression in colorectal tissue | Pharmacogenomics and Personalized Medicine | 2017 | 28 |
| 41 | CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors | Pharmacogenomics and Personalized Medicine | 2013 | 28 |
| 42 | Economic evaluations of personalized medicine: existing challenges and current developments | Pharmacogenomics and Personalized Medicine | 2015 | 27 |
| 43 | Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics | Pharmacogenomics and Personalized Medicine | 2015 | 27 |
| 44 | The utility of pharmacogenetic testing to support the treatment of bipolar disorder | Pharmacogenomics and Personalized Medicine | 2018 | 27 |
| 45 | Pharmacogenomic considerations in opioid analgesia | Pharmacogenomics and Personalized Medicine | 2012 | 26 |
| 46 | CYP2D6 polymorphisms and their influence on risperidone treatment | Pharmacogenomics and Personalized Medicine | 2016 | 26 |
| 47 | Initial assessment of the benefits of implementing pharmacogenetics into the medical management of patients in a long-term care facility | Pharmacogenomics and Personalized Medicine | 2016 | 26 |
| 48 | Dysregulation of the homeobox transcription factor gene HOXB13: role in prostate cancer | Pharmacogenomics and Personalized Medicine | 2014 | 25 |
| 49 | Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives | Pharmacogenomics and Personalized Medicine | 2016 | 25 |
| 50 | <p>Pharmacogenomics And Hypertension: Current Insights</p> | Pharmacogenomics and Personalized Medicine | 2019 | 25 |
